Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Citations 0
Lab Reports
April 6, 2011

Mucosal HIV Protection

JAMA. 2011;305(13):1290. doi:10.1001/jama.2011.385

An international research team has demonstrated that a vaccine that stimulates production of anti-HIV antibodies in vaginal tissue can protect monkeys from HIV infection (Bomsel M et al. Immunity. 2011;34[2]:269-280).

Acquisition of HIV through sexual intercourse mainly occurs at mucosal sites, but vaccine strategies under investigation usually aim to induce neutralizing antibodies or cytotoxic T cells circulating in the blood. An alternative vaccine strategy could be to elicit a mucosal immune response to block viral entry at mucosal sites. In this case, researchers sought to elicit IgA antibodies specific for gp41, HIV's most conserved envelope subunit. These antibodies have previously been shown to block HIV infection of mucosal cells.

First Page Preview View Large
First page PDF preview
First page PDF preview